Peloton Therapeutics, Inc. Company Profile

23:47 EST 14th December 2018 | BioPortfolio

Peloton Therapeutics is a drug discovery and development company focused on advancing first-in-class small molecule therapies for cancer and other life-threatening diseases. Initial efforts are focused on hypoxia inducible factor-2α (HIF-2α), which has been implicated in the development and progression of several types of cancers. Peloton’s lead candidate, PT2385, is the first HIF-2α inhibitor to enter clinical development and is being evaluated in a Phase 1 clinical trial for the treatment of advanced or metastatic clear cell renal cell carcinoma (ccRCC). Peloton is headquartered in Dallas, TX and was founded in 2011 by Professor Steven McKnight and The Column Group. The company raised more than $30 million in a Series C financing in October 2014 to fund its development activities for PT2385 as well as advance its research pipeline. Peloton is backed by The Column Group, Remeditex Ventures, Tichenor Ventures, Topspin Fund, Nextech Invest, and other investors. For more information, please visit

News Articles [716 Associated News Articles listed on BioPortfolio]

Peloton doses first patient in Phase ll trial of PT2977

Peloton Therapeutics has dosed the first patient in a Phase ll trial investigating the efficacy and safety of PT2977 for...Read More... The post Peloton doses first patient in Phase ll trial of PT2977...

The Five Ways Peloton Weave Community and Content Beautifully

Peloton have re-invented the ubiquitous exercise bike, using a carefully crafted content and community strategy to make it tick. Here are five elements of that strategy that are fueling their success.

[:en]Open Health merges with med comms services provider Peloton[:]

[:en]UK-based Open Health Communications has merged with Peloton Advantage to create a global healthcare communications and market access group. The combined company will continue under the Open Heal...

Peloton Therapeutics Appoints Alan A. Musso Chief Financial Officer

Peloton Therapeutics, Inc., today announced the appointment of Alan A. Musso as Chief Financial Officer (CFO), effective September 4, 2018. Mr. Musso brings significant financial ...

OPEN Health merges with Peloton Advantage

Health communications and market access group OPEN Health has merged with medical communications firm Peloton Advantage in a move designed to broaden the range of services available to clients.

Peloton Therapeutics Announces Appointment of John Moore as General Counsel and Corporate Secretary

Peloton Therapeutics, Inc., a clinical-stage pharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced today that John Moor...

Swarmlike collective behavior in bicycling

Nature is full of examples of large-scale collective behavior; humans also exhibit this behavior, most notably in pelotons, the mass of riders in bicycle races. Using aerial video footage of bicycle r...

Peloton Therapeutics Initiates Phase 2 Trial of Oral HIF-2α Inhibitor PT2977 for Treatment of von Hippel-Lindau Disease-associated Kidney Cancer

Peloton Therapeutics, Inc., announced today dosing of the first patient in a Phase 2 trial evaluating the efficacy and safety of lead investigational oncology agent, PT2977, to tr...

PubMed Articles [460 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1287 Associated Companies listed on BioPortfolio]

Peloton Advantage, LLC

Peloton Advantage, LLC is a privately owned medical communications company specializing in strategic publication planning and associated content development for medical education ...

Peloton Therapeutics, Inc.

Peloton Therapeutics is a drug discovery and development company focused on advancing first-in-class small molecule therapies for cancer and other life-threatening diseases. Initi...

The Peloton

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Peloton Therapeutics, Inc." on BioPortfolio

We have published hundreds of Peloton Therapeutics, Inc. news stories on BioPortfolio along with dozens of Peloton Therapeutics, Inc. Clinical Trials and PubMed Articles about Peloton Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Peloton Therapeutics, Inc. Companies in our database. You can also find out about relevant Peloton Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Corporate Database Quicklinks

Searches Linking to this Company Record